T1	Participants 33 81	relapsing-remitting multiple sclerosis (SELECT):
T2	Participants 424 479	in patients with relapsing-remitting multiple sclerosis
T3	Participants 549 694	at 76 centres in the Czech Republic, Germany, Hungary, India, Poland, Russia, Ukraine, Turkey, and the UK between Feb 15, 2008, and May 14, 2010.
T4	Participants 695 764	Patients aged 18-55 years with relapsing-remitting multiple sclerosis
T5	Participants 1285 1392	FINDINGS 204 patients were assigned to receive placebo, 208 to daclizumab HYP 150 mg, and 209 to daclizumab
T6	Participants 2519 2559	treatment option for relapsing-remitting
